Business Description
Mendus AB
ISIN : SE0022239950
Total Employee Number:
19Compare
Compare
Traded in other countries / regions
IMMU.Sweden1YG0.GermanyIMMUs.UK IPO Date
2013-04-22Description
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.16 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 44.9 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 48.1 | |||||
3-Year Book Growth Rate | -41.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.69 | |||||
9-Day RSI | 54.93 | |||||
14-Day RSI | 55.35 | |||||
3-1 Month Momentum % | 17.12 | |||||
6-1 Month Momentum % | -9.88 | |||||
12-1 Month Momentum % | -39.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.53 | |||||
Quick Ratio | 1.53 | |||||
Cash Ratio | 1.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -78.2 | |||||
Shareholder Yield % | 1.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -17.66 | |||||
ROA % | -16.25 | |||||
ROIC % | -17.66 | |||||
3-Year ROIIC % | -45.45 | |||||
ROC (Joel Greenblatt) % | -420.51 | |||||
ROCE % | -16.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.66 | |||||
PB Ratio | 0.66 | |||||
Price-to-Tangible-Book | 11.53 | |||||
EV-to-EBIT | -3.19 | |||||
EV-to-EBITDA | -3.4 | |||||
EV-to-Forward-EBITDA | -3.61 | |||||
EV-to-Forward-Revenue | 31.81 | |||||
EV-to-FCF | -3.64 | |||||
| Price-to-Net-Current-Asset-Value | 30.55 | |||||
| Price-to-Net-Cash | 76.38 | |||||
Earnings Yield (Greenblatt) % | -31.35 | |||||
FCF Yield % | -23.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mendus AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.9 | ||
| Beta | 1.0626 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.39 | ||
| Volatility % | 52.94 | ||
| 14-Day RSI | 55.35 | ||
| 14-Day ATR (kr) | 0.447925 | ||
| 20-Day SMA (kr) | 5.837 | ||
| 12-1 Month Momentum % | -39.53 | ||
| 52-Week Range (kr) | 3.86 - 10.98 | ||
| Shares Outstanding (Mil) | 61.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mendus AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mendus AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-11 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 46 days | ||
| General meeting for 2026 | 2026-05-08 09:00 | 4.56 (-4.51%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 4.56 (-4.51%) | ||
| Annual report for 2025 | 2026-04-17 | 4.98 (+1.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-11 14:00 | 4.91 (-0.91%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-11 | 4.91 (-0.91%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 14:00 | 5.90 (+4.24%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 5.90 (+4.24%) |
Show
Entries
Mendus AB Frequently Asked Questions
What is Mendus AB(OSTO:IMMU)'s stock price today?
The current price of OSTO:IMMU is kr6.11. The 52 week high of OSTO:IMMU is kr10.98 and 52 week low is kr3.86.
When is next earnings date of Mendus AB(OSTO:IMMU)?
The next earnings date of Mendus AB(OSTO:IMMU) is 2026-08-20.
Does Mendus AB(OSTO:IMMU) pay dividends? If so, how much?
Mendus AB(OSTO:IMMU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Mendus AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers